PTPRZ1 and neoplasm: The PTPRZ1 peptides, together with the rest of the HLA-A2-restricted tumor-associated antigens identified by peptidomics, have been used to formulate a multi-peptide vaccine (IMA950) that has entered phase I/II clinical trials for gliomas and showed spontaneous antigen-specific T-cell responses that were better in grade II and III compared to GBM patients [125].